Cargando…
Durable Response to Nivolumab in a Patient With Hepatic Sarcomatoid Carcinoma: Evolutive Characterization of Genomic and Immunohistochemical PD-L1 Expression Findings
Autores principales: | Queiroz, Marcello M., Munhoz, Rodrigo R., Masotti, Cibele, Souza, Larissa M., Lima, Luiz G.C.A., Asprino, Paula F., Begnami, Maria Dirlei F.S., Camargo, Anamaria A., Bettoni, Fabiana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489170/ https://www.ncbi.nlm.nih.gov/pubmed/36044716 http://dx.doi.org/10.1200/PO.22.00163 |
Ejemplares similares
-
Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
por: Xavier, Camila B, et al.
Publicado: (2023) -
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020) -
Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series
por: Hashimoto, Kentaro, et al.
Publicado: (2022) -
Choice of 16S Ribosomal RNA Primers Impacts Male Urinary Microbiota Profiling
por: Heidrich, Vitor, et al.
Publicado: (2022) -
Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis
por: Salati, Massimiliano, et al.
Publicado: (2018)